NBTXNanobiotix S.A.
43.55USDMkt Cap: 2.21B $P/E: —3d ago
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap2.21B $
Enterprise Value2.16B $
Revenue (TTM)32.59M $
Gross Profit32.59M $
Net Income (TTM)-23.96M $
Revenue/Share0.6820 USD
Last Price43.55 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-127.63
PEG—
EV/EBITDA-205.56
EV/Revenue66.15
P/S68.09
P/B-21.61
EPS (TTM)-0.56
EPS (Forward)-0.34
52W Range
43.1227% of range44.69
52W High44.69 USD
52W Low43.12 USD
Profitability
Gross Margin100.00%
Oper. Margin-196.42%
EBITDA Margin-32.18%
Profit Margin-80.83%
ROE28.36%
ROA-35.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.42M $
CapEx (TTM)546.00K $
FCF Margin-24.22%
FCF Yield-0.36%
Net Debt42.57M $
Net Debt/EBITDA-4.06
Balance Sheet
Debt/Equity-1.13
Current Ratio1.09
Quick Ratio1.05
Book Value/Sh-2.0212 USD
Cash/Share1.090 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)45.58 USD
Upside (mean)+4.7%
Target Range29.90 USD – 70.61 USD
$29.90+4.7% to mean$70.61
# Analysts3
Ownership
Shares Out.50.80M
Float31.95M
Insiders0.00%
Institutions11.95%
Short Interest
Short Ratio0.8d
Short % Float0.27%
Short % Out.0.20%
Shares Short99.41K
Short (prev mo.)52.50K
Technical
SMA 5038.17 (+14.1%)
SMA 20030.93 (+40.8%)
Beta0.57
S&P 52W Chg21.00%
Avg Vol (30d)74.17K
Avg Vol (10d)182.65K
Technical Indicators
RSI (14)59.3
MACD1.1915
MACD Signal0.5911
MACD Hist.+0.6004
BB Upper44.43 USD
BB Middle39.75 USD
BB Lower35.08 USD
BB Width23.51%
ATR (14)2.755 USD
Vol Ratio (20d)0.48x